{"filing":{"accession_number":"0001833141-26-000041","cik":"0001833141","ticker":"HELP","company_name":"CYBIN INC.","form":"6-K","filing_date":"2026-06-25","report_date":null,"primary_document":"cybininc-form6xk06x25x2026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1833141/000183314126000041/cybininc-form6xk06x25x2026.htm"},"events":[{"id":13796,"run_id":12255,"accession_number":"0001833141-26-000041","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This press release announces the closing of a US$50 million underwritten public offering of 10,309,280 common shares at US$4.85 per share. The offering was conducted pursuant to a prospectus supplement and Form F-10 registration statement filed with the SEC, representing a material dilutive issuance of equity securities. The proceeds are earmarked for clinical development programs and working capital, making this a significant capital-raising event for the clinical-stage pharmaceutical company.","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-06-25","form":"6-K","submitted_at":null,"items":[{"id":11046,"accession_number":"0001833141-26-000041","item_number":"EX-99.1","item_title":"finalpressrelease-closingo.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This press release announces the closing of a US$50 million underwritten public offering of 10,309,280 common shares at US$4.85 per share. The offering was conducted pursuant to a prospectus supplement and Form F-10 registration statement filed with the SEC, representing a material dilutive issuance of equity securities. The proceeds are earmarked for clinical development programs and working capital, making this a significant capital-raising event for the clinical-stage pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T15:05:37.443835+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11046,"accession_number":"0001833141-26-000041","item_number":"EX-99.1","item_title":"finalpressrelease-closingo.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This press release announces the closing of a US$50 million underwritten public offering of 10,309,280 common shares at US$4.85 per share. The offering was conducted pursuant to a prospectus supplement and Form F-10 registration statement filed with the SEC, representing a material dilutive issuance of equity securities. The proceeds are earmarked for clinical development programs and working capital, making this a significant capital-raising event for the clinical-stage pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T15:05:37.443835+00:00","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-06-25"}]}